Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.37 |
| ▸ | PDE2A | O00408 | 3/20 | 0.35 |
| ▸ | GSK3B | P49841 | 5/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | PIK3R2 | O00459 | 3/20 | 0.32 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.31 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24010663 | 0.92 | PDE10A (0.38) | PDE10AGSK3BSYKCYP1A2CYP2D6 | |
| SCHEMBL24010661 | 0.92 | PDE10A (0.38) | PDE10AGSK3BSYKCYP1A2CYP2D6 | |
| SCHEMBL30160660 | 0.92 | PDE10A (0.38) | PDE10AGSK3BSYKCYP1A2CYP2D6 | |
| SCHEMBL24009712 | 0.92 | PDE10A (0.38) | PDE10AGSK3BSYKCYP1A2CYP2D6 | |
| SCHEMBL24009296 | 0.87 | PDE10A (0.35) | PDE10APDE2AGSK3BCYP1A2CYP2D6 | |
| SCHEMBL30160309 | 0.87 | PDE10A (0.35) | PDE10APDE2AGSK3BCYP1A2CYP2D6 | |
| SCHEMBL24010823 | 0.87 | PDE10A (0.35) | PDE10APDE2AGSK3BCYP1A2CYP2D6 | |
| SCHEMBL24010664 | 0.87 | PDE10A (0.35) | PDE10APDE2AGSK3BCYP1A2CYP2D6 | |
| SCHEMBL24009649 | 0.86 | PDE10A (0.38) | PDE10APDE2AGSK3BCYP1A2CYP2D6 | |
| SCHEMBL24009897 | 0.85 | PDE10A (0.36) | PDE10APDE2AGSK3BSYKCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295170-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295169-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295170-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295169-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230002390-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002390-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | PDE10A 3729/4885PDE2A 2161/4885GSK3B 3421/4885 |
| US-20230295169-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | PDE10A 3729/4885PDE2A 2161/4885GSK3B 3421/4885 |
| US-20230295170-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | PDE10A 3729/4885PDE2A 2161/4885GSK3B 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.